A case series of BRAF V600E inhibitor (PLX4032) related cutaneous eruptions in metastatic melanoma

被引：0
|
作者：
Sinha, R. [1 ]
Fearfield, L. [2 ]
Larkin, J. [1 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2011年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [11] Molecular Testing for BRAF V600 Mutations in Clinical Trials of the BRAF Inhibitor Vemurafenib (RG7204/PLX4032) in Metastatic Melanoma - a Comparison With Sanger Sequencing
    Anderson, S.
    Bloom, K.
    Schilling, R.
    Lee, J. R. J.
    Langland, R.
    Halait, H.
    Lawrence, H. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S170 - S170
  • [12] Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
    Rubinstein, Jill C.
    Sznol, Mario
    Pavlick, Anna C.
    Ariyan, Stephan
    Cheng, Elaine
    Bacchiocchi, Antonella
    Kluger, Harriet M.
    Narayan, Deepak
    Halaban, Ruth
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [13] Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
    Jill C Rubinstein
    Mario Sznol
    Anna C Pavlick
    Stephan Ariyan
    Elaine Cheng
    Antonella Bacchiocchi
    Harriet M Kluger
    Deepak Narayan
    Ruth Halaban
    Journal of Translational Medicine, 8
  • [14] Clinical Utility of Combining PLX4032, a BRAF Inhibitor, with a Multivalent Melanoma Immunotherapeutic Vaccine
    Wallack, M.
    Suriano, R.
    Tuli, N.
    George, A. L.
    Geliebter, J.
    Tiwari, R. K.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S124 - S124
  • [15] The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
    Jenkins, Molly H.
    Croteauz, Walburga
    Mullins, David W.
    Brinckerhoff, Constance E.
    MATRIX BIOLOGY, 2015, 48 : 66 - 77
  • [16] Analysis of the BRAF V600E mutation in primary cutaneous melanoma
    Inumaru, J. S. S.
    Gordo, K. I. F.
    Fraga Junior, A. C.
    Silva, A. M. T. C.
    Leal, C. B. Q. S.
    Ayres, F. M.
    Wastowski, I. J.
    Borges, N. F.
    Saddi, V. A.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) : 2840 - 2848
  • [17] Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma
    Poudel, Muna
    Kim, Garam
    Bhattarai, Poshan Yugal
    Shin, Seung
    Zaraei, Seyed-Omar
    Oh, Chang-Hyun
    Choi, Hong Seok
    ANTICANCER RESEARCH, 2022, 42 (06) : 2911 - 2921
  • [18] Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Sondergaard, Jonas N.
    Nazarian, Ramin
    Wang, Qi
    Guo, Deliang
    Hsueh, Teli
    Mok, Stephen
    Sazegar, Hooman
    MacConaill, Laura E.
    Barretina, Jordi G.
    Kehoe, Sarah M.
    Attar, Narsis
    von Euw, Erika
    Zuckerman, Jonathan E.
    Chmielowski, Bartosz
    Comin-Anduix, Begona
    Koya, Richard C.
    Mischel, Paul S.
    Lo, Roger S.
    Ribas, Antoni
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [19] A role for immunohistochemical detection of BRAF V600E in metastatic melanoma?
    Lade-Keller, J.
    Kristensen, L. S.
    Riber-Hansen, R.
    Guldberg, P.
    Hansen, L. L.
    Steiniche, T.
    Hager, H.
    APMIS, 2013, 121 : 7 - 7
  • [20] Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
    Fedorenko, Inna V.
    Paraiso, Kim H. T.
    Smalley, Keiran S. M.
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (03) : 201 - 209
12345